Wellington Shields Capital Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Wellington Shields Capital Management’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-1,275	Closed	-$47K	–	371
2013 Q4	$47K	Buy	1,275 +1,025	+410%	+$97.1K	0.01%	314
2013 Q3	$26K	Hold	250	–	–	0.01%	316
2013 Q2	$19K	Buy	+250	New	+$23.9K	﹤0.01%	336

Other funds holding IMUC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Shields Capital Management's IMUC Position: Q1 2014 in Review

Wellington Shields Capital Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q1 2014, closing a stake of 1,275 shares — an estimated $47K sold.

Wellington Shields Capital Management first reported a position in IMUC in Q2 2013 and held it in 3 quarters. The position peaked at $47K in Q4 2013. 36 funds tracked by Wall St. Rank hold IMUC as of Q1 2014.

Wellington Shields Capital Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q1 2014 after selling out during the quarter.
Wellington Shields Capital Management sold 1,275 ImmunoCellular Therapeutics, Ltd. shares in Q1 2014, an estimated $47K.
Wellington Shields Capital Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 3 quarters.
Wellington Shields Capital Management's ImmunoCellular Therapeutics, Ltd. position peaked at $47K in Q4 2013.
36 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q1 2014.

Based on Wellington Shields Capital Management's 13F filing for Q1 2014, filed 13 May 2014.